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Abstract
Purpose To assess the impact of manual lymphatic drainage (MLD) on the health-related quality of life (HRQoL) of adults 
with lymphoedema or mixed oedema, through a systematic review of randomised controlled trials (RCTs).
Methods MEDLINE, EMBASE, PsycINFO, CENTRAL, the Cochrane Database of Systematic Reviews and ClinicalTri-
als.gov were searched to identify RCTs evaluating HRQoL after a MLD intervention compared to non-MLD interven-
tions (PROSPERO 2016:CRD42016042255). We extracted the effect of the interventions on the HRQoL (primary outcome) 
as well as data on volume and functional changes, and adverse events when available (secondary outcomes).
Results Eight studies were eligible. The studies were heterogeneous in the aetiology of oedema, schemes of MLD applied, 
additional treatments offered with MLD, length of follow-up, instruments used to assess HRQoL and interventions offered to 
the control group. Five studies included patients with breast cancer-related arm lymphoedema; one study reported increased 
HRQoL among patients randomised to the MLD group. The two RCTs that involved patients with leg mixed oedema due 
to chronic venous insufficiency did not find between-group differences in the overall HRQoL. One trial included patients 
with hand oedema from systemic sclerosis and showed higher HRQoL in the group that received MLD. No studies reported 
reductions in HRQoL, or severe adverse events after MLD. The small numbers of patients analysed in all studies may have 
resulted in lack of power to detect between-group differences in HRQoL.
Conclusions The effect of MLD on the HRQoL of patients with chronic oedema is unclear.
Keywords Quality of life · Musculoskeletal manipulations · Edema · Review · Systematic
Introduction
Lymphoedema is a chronic abnormal swelling of a limb or 
quadrant of the trunk due to accumulation of protein-rich 
fluids in the interstitial tissue, caused by incapacity of the 
lymphatic system to effectively distribute lymph [1, 2]. Most 
lymphoedema cases are secondary to cancer treatments such 
as lymphadenectomies and/or radiotherapy [3, 4]. Breast 
cancer patients are particularly affected, with nearly 20% of 
the women who have axillary lymph node dissection devel-
oping lymphoedema of the arm [5, 6].
Mixed oedema, also called lymphaticovenous oedema, 
is a form of chronic oedema that results from damages to 
the lymphatic system caused by prolonged volume overload 
from venous diseases, such as post-thrombotic syndrome or 
chronic venous insufficiency [7–9].
Chronic oedema may have severe physical and psy-
chological consequences for patients, including impaired 
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physical function, recurrent infections, ulcerations, pain, 
limb numbness, heaviness and tightness, as well as reduced 
quality of life [10–13]. Guidelines for the management of 
breast cancer-related lymphoedema (BCRL) recommend the 
use of complete decongestive therapy (CDT) [1, 2], which 
includes manual lymphatic drainage (MLD), self-care (e.g. 
healthy diet, skin care), physical exercise and compression 
therapy with bandaging or garments [14]. CDT is also used 
in the management of mixed oedema [15, 16]. MLD consists 
of special massage techniques with gentle tissue pressure to 
promote lymph flow [14]. It is considered effective in reduc-
ing lymphoedema [17]. Nevertheless, besides understand-
ing the impact of MLD on clinical endpoints (e.g. changes 
in volume or appearance of ulceration), understanding the 
MLD impact on patients’ perception, including the health-
related quality of life (HRQoL) is essential to develop com-
prehensive therapy concepts.
To the best of our knowledge, no systematic review aimed 
to evaluate the effect of MLD on the HRQoL of patients 
with lymphoedema or mixed oedema. A systematic review 
that aimed to assess the efficacy and safety of MLD to treat 
BCRL included two trials that also evaluated quality of life; 
however, none of the trials presented results for between-
group comparisons  and thus the effect of MLD on HRQoL 
was inconclusive [18]. A systematic review on the quality of 
life of patients with cancer-related lower limb lymphoedema 
suggested that CDT may improve HRQoL, but this conclu-
sion was based on two small observational studies [15].
We aimed to evaluate the impact of MLD on the HRQoL 
of adult patients with lymphoedema or mixed oedema, irre-
spective of the oedema aetiology or location, through a sys-
tematic review of randomised controlled trials (RCTs).
Methods
The review protocol was registered at the international 
prospective register of systematic reviews (PROSPERO 
2016:CRD42016042255).
Search strategy
We searched MEDLINE, EMBASE and PsycINFO via 
OvidSP®, and the Cochrane Central Register of Controlled 
Trials (CENTRAL), the Cochrane Database of Systematic 
Reviews and ClinicalTrials.gov, from inception up to June 
2016. The search expressions are provided in Online Appen-
dix S1. In addition, the reference lists of the eligible studies 
and of the systematic reviews were manually screened to 
identify additional studies.
Criteria for considering studies for this systematic 
review
RCTs including patients with lymphoedema or mixed 
oedema, in which MLD or CDT (exposure) was the primary 
intervention given to the intervention group (IG) and not to 
the control group (CG), and providing results for HRQoL, 
were eligible. There were no restrictions in the aetiology 
of oedema, affected body region, or duration or frequency 
of the MLD intervention. We considered as eligible studies 
involving patients with post-thrombotic syndrome because 
mixed oedema is part of the natural course of the disease 
[19–21]. Studies involving patients with chronic venous 
insufficiency in the grade of oedema (> C2, as measured 
by the Clinical-Etiologic-Anatomic-Pathophysiologic score 
[22]) were also eligible.
The following exclusion criteria were defined a priori and 
applied: observational study design; studies not including 
adults (< 18 years); RCTs that did not include patients with 
lymphoedema or mixed oedema; RCTs with a primary inter-
vention other than MLD; RCTs in which the CG received 
MLD or a MLD-like intervention (e.g. self-lymphatic drain-
age or automatic-MLD performed by technical devices, as 
these interventions may attenuate the between-group dif-
ferences); RCTs not providing measurements of HRQoL 
(overall or domains) before and after the intervention in 
both groups and RCTs not providing sufficient data for a 
comparison of the primary outcome data in CG and IG. No 
language criterion was applied.
Selection of studies
Two reviewers (MM, KS) independently screened the ref-
erences, applying the inclusion and exclusion criteria (see 
above). The studies were evaluated in two steps: first con-
sidering the information provided in the title and abstract, 
and then the full-text. When the violation of a criterion could 
not be determined unequivocally, the article was considered 
for further evaluation.
Differences in the decision of the two reviewers were 
solved by discussion and involving a third researcher (HC) 
when necessary.
Data extraction
The following data were extracted using a pre-defined form: 
characteristics of the studies (e.g. RCT design; data to eval-
uate the risk of bias); characteristics of the study popula-
tion (e.g. age at trial enrolment, sex distribution, aetiology 
of the oedema and affected body part); characteristics of 
the intervention (e.g. duration and frequency of the MLD 
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intervention and additional interventions) and outcome data 
(e.g. mean or median scores of HRQoL summary measures, 
or of HRQoL domains, as available, and results of hypoth-
esis tests). When a trial reported results for more than one 
follow-up time, we extracted the data for the first follow-up 
after the MLD intervention; this aimed to reduce between-
trial variability in the time elapsed since the intervention and 
the evaluation of the outcome.
In one study with three treatment groups, the two groups 
in which the interventions differed only in the MLD-treat-
ment were included in the analysis [23]. In one cross-over 
trial, only first cycle data were extracted to avoid carry-over 
and period effects [24].
Risk of bias
The risk of bias was assessed based on the domains pro-
posed by the Cochrane Collaboration’s for intervention stud-
ies [24]. We sought information to evaluate the potential for 
selection bias due to lack of randomisation and allocation 
concealment. Patients cannot be blinded to the MLD inter-
vention; however, we kept this item in our assessment to 
highlight the potential for detection bias.
Bias could also have occurred in the trials if the adher-
ence to, or the quality of MLD intervention, were subopti-
mal. The risk of bias due to lack of adherence to MLD was 
considered low when patients in the IG attended at least 75% 
of the initially planned number of MLD sessions, high when 
patients attended less than 75% of the sessions and unclear 
when the number of attended sessions was not reported 
[18]. A low risk in quality of MLD satisfies the property 
that skilled therapists performed the MLD intervention.
Information on the quality of the studies was used to com-
ment on the results.
Data synthesis
The primary outcome was overall HRQoL, as defined by the 
authors of the original studies. Overall HRQoL and HRQoL 
domains are often measured with several psychometric 
scales. The HRQoL domains from the conceptual framework 
of the Short Form Health Survey 36 [25], a widely used and 
accepted HRQoL questionnaire, were used to group indi-
vidual domains reported by the different HRQoL instru-
ments. Therefore, we summarised data under the following 
domains of HRQoL: physical, social, psychological/mental, 
role functioning, body pain, vitality and general.
Descriptive tables were used to summarise the mean/
median scores between the IG and the CG (between-group 
differences), as well as the pre- and post-intervention mean/
median scores within each group. Study results are described 
by oedema aetiology and affected body region.
The statistical significance level of the between-group 
differences is for the comparisons of the post-intervention 
HRQoL measure, or the mean difference of the treatment 
effect (pre-post value), between IG and CG, as reported in 
the original studies.
Follow-up time, defined as the time elapsed between 
the last MLD-treatment and the HRQoL assessment, was 
grouped into three categories: (1) immediate follow-up, if 
HRQoL was measured between 1 day and 2 weeks follow-
ing the last treatment; (2) short-term follow-up, if between 
2 weeks and 12 weeks; (3) intermediate-term follow-up, if 
more than 12 weeks.
Meta-analytic methods were not used due to the hetero-
geneity of the eligible trials regarding the study populations, 
LE definition, interventions offered to intervention and con-
trol groups, instruments used to quantify HRQoL and time 
elapsed between MLD and assessment of HRQoL.
Results
Out of 3456 references identified in the electronic databases, 
37 full-text papers were assessed for eligibility and eight [23, 
26–32] were included in the analysis (Fig. 1).
In the eight eligible studies, three study populations, 
areas and aetiologies of lymphoedema were identified: arm 
BCRL (five studies [23, 26, 28, 29, 31]), mixed oedema from 
venous diseases in the legs (two studies [30, 32]) and hand 
oedema from systemic sclerosis (1 study [27]) (Table 1).
Risk of bias
The risk of bias due to unbalanced probability of group allo-
cation was low in most studies. However, in one study the 
computer-generated random list was not concealed [31] and 
this information was unclear in four others [23, 28, 29, 32]. 
Performance bias was judged high for all trials because the 
physical nature of the intervention precludes the blinding of 
the patients to the exposure. The risk of attrition bias was 
considered high in four studies [27–29, 31] due to imbal-
ances in the number of withdrawals that could be related to 
the outcome between the groups (Fig. 2).
The baseline characteristics did not show any signifi-
cant differences between IG and CG, except for the study 
[28] where patients in the IG suffered from more severe 
lymphoedema.
Breast cancer‑related lymphoedema
Five studies included women who developed lymphoe-
dema after breast cancer treatments [23, 26, 28, 29, 31]. 
The studies used different criteria to define lymphoedema, 
including clinical diagnosis [26, 31] as well as measures of 
1406 Quality of Life Research (2018) 27:1403–1414
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limb volume difference [23, 28, 29]. All trials included few 
patients in analysis, ranging from 16 [23] to 56 [28] in the 
IG and from 10 [31] to 39 [28] in the CG.
Heterogeneity was also observed in the interventions 
offered in addition to MLD to the IGs and to the CGs. CDT 
was the primary intervention in three studies [26, 28, 29]; 
other concomitant interventions were exercise [31] and low-
level laser therapy [23]. The schemes of MDL-sessions used 
in the trials varied from 15 min, twice a week, over 6 weeks 
[31] to 60 min, five times a week, during 4 weeks [28]. Con-
trol interventions consisted of exercise, CDT without MLD, 
electrotherapy and laser therapy (Table 1).
All but one study assessed HRQoL with a breast cancer- 
or lymphoedema-specific questionnaire (Online Appen-
dix S2). Odebiyi et al. [31] used a generic instrument for 
cancer patients (the European Organisation for Research 
and Treatment of Cancer quality-of-life questionnaire). 
The domains covered by each instrument are provided in 
Online Appendix S3. Most trials used instruments that 
included domains for physical and psychological function-
ing [23, 26, 28, 29] and pain [26, 29]. The first outcome 
evaluation was mostly performed immediately after the 
last MLD-treatment [23, 26, 28] (Table 1).
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Table 2 summarises the main results of the comparison 
of overall HRQoL and HRQoL domains between the inter-
vention and control group, as well as the comparison of 
pre- and post-intervention. Statistical evidence for improved 
HRQoL in the group offered MLD was found in one study 
only (MLD and physical exercise vs. physical exercise) [31] 
(Table 2). In the study by Gradalski et al. [29], the overall 
HRQoL did not differ between the two groups, but the group 
offered MLD reported significant improvements in social 
functioning.
Within each group, overall HRQoL generally improved 
from pre- to post-intervention (Online Appendix S3); some 
statistical evidence of within group improvements was 
reported by Gradalski et al. (CDT vs. CDT without MLD) 
[29], Odebiyi et al. (MLD and physical exercise vs. physical 
exercise) [31] and Ridner et al. (MLD and low-level laser 
therapy vs. low-level laser therapy) [23], both for the inter-
vention and control groups (Table 2). Gradalski et al. [29] 
also reported significant improvements in well-being feel-
ings, lymphoedema-related pain, limb heaviness and size, 
skin tension, in addition to less sleep disturbances and skin 
infections, both in the intervention and in the control group, 
even though there were no statistically significant differences 
between the two groups (Online Appendix S3).
Almost all trials reported lymphoedema and upper limb 
volume measurements (Table 3). A reduction in lymphoe-
dema volume pre- and post-intervention was noted in all tri-
als [23, 26, 28, 29]. However, only Dayes et al. [28] reported 
a significant reduction in the absolute lymphoedema volume 
in the intervention group, compared to the control group.
Adverse events were rarely reported. The few cases 
reported included temporary rash, pain and one episode each 
of cellulitis [28] and erysipelas [26] (Table 3).
Leg mixed oedema
Two studies included patients diagnosed with mixed oedema 
from venous diseases [30, 32]. Holmes et al. [30] included 
31 patients with post-thrombotic syndrome and evaluated 
the effect of MLD as part of CDT compared to compression 
bandaging alone. Dos Santos Crisostomo et al. [32] analysed 
data for 41 patients with chronic venous insufficiency, to 
compare the effect of ten sessions (45 min) of MLD over four 
weeks and an educational session, to that of the educational 
session alone. The evaluation of the outcome was performed 
immediately after the last intervention in both studies, using 
disease-specific instruments that include items for oedema 
(Table 1). Overall HRQoL was not significantly different 
between the intervention and control group in neither study. 
Significant differences in HRQoL were, however, reported 
for patients with post-thrombotic syndrome receiving either 
therapy but who did not wear stockings before the study, 
compared to those who wore the stockings [30] (Table 2). 
Further a posteriori analyses revealed that those with more 
severe post-thrombotic syndrome had greater improvements 
in HRQoL after either treatment, but these results were not 
statistically significant. Within group differences pre- and 
post-intervention were only reported for pain and fatigue 
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by patients with chronic venous insufficiency who received 
MLD and an educational session [32] (Table 2).
Adverse events included three cases of deep venous 
thrombosis (IG: n = 1; CG n = 2) [30], and one case each 
of superficial thrombophlebitis and stocking allergy in the 
compression garments only group [30] (Table 3).
Hand oedema in patients with systematic sclerosis
One study assessed the effect of MLD on the HRQoL of 
20 patients with systemic sclerosis and clinically diag-
nosed hand oedema, compared to observation alone (con-
trol group, n = 20) [27] (Table 1). The results showed 
significant improvements in HRQoL in the IG (one hour 
session of MLD per week, over 5 weeks) compared to 
the placebo CG [27]. The difference in overall HRQoL 
was accompanied by between-group differences in the 
physical, mental, role functioning and pain domains [27] 
(Table 2). Significant changes in HRQoL between baseline 
and the end of treatment were reported in the IG only, 
for overall HRQoL as well as for the physical and mental 
components [27]. The volume of the hand and of oedema 
reduced significantly after the MLD intervention, and the 
volume post-MLD was significantly lower when compared 
to the women in the CG [27]. No adverse events were 
reported [27].
Discussion
Summary of main results
We found conflicting evidence of the impact of MLD on 
the HRQoL of adult patients with lymphoedema or mixed 
oedema. Most studies showed that MLD did not signifi-
cantly increase the HRQoL of the patients with BCRL 
or mixed oedema due to venous diseases. However, sig-
nificant increases in HRQoL or some of its domains were 
reported in patients with systemic sclerosis and hand 
oedema, and in one out of the five studies that included 
patients with BCRL. The studies were heterogeneous in 
regard to the definition of lymphoedema, interventions 
offered to the intervention and control groups across tri-
als and the time points at which the HRQoL was evaluated. 
In summary, the quantity, quality and heterogeneity of the 
trials preclude definitive conclusions.
Table 3  Adverse events and secondary outcomes reported by the trials: comparison between intervention and control groups (BG) and pre- and 
post-treatment in the intervention group (PP)
BG between-group difference, CG control group, DVT deep venous thrombosis, HRQoL health-related quality of life, IG intervention group, 
MLD manual lymphatic drainage, n.r. not reported (unable to determine if assessed), PP pre- vs. post-intervention difference in the outcomes 
reported by the IG
“▲”, statistical evidence against the null hypothesis of no difference between the treatment groups in the outcome (p < 0.05), i.e. there is evi-
dence that there is a benefit of MLD concerning the outcome
“○”, no evidence against the null hypothesis (p ≥ 0.05)
a Cross-over trial: treatment effects/adverse events in the whole sample (both) groups
b In 17 patients
c Most events consisted of temporary rash or mild to moderate pain. One episode of cellulitis and severe pain occurred in the IG
d In 7 patients
First author (year of publication) Adverse events Oedema volume Volume 
affected body 
part
Functional 
outcomes
IG CG BG PP BG PP BG PP
Belmonte (2012) [26]a None 1 erysipelas ○ ▲ – – – –
Dayes (2013) [28] 19  eventsb,c 9  eventsc,d Absolute:▲ ▲ – – – –
Relative:○ –
Gradalski (2015) [29] n.r. n.r. ○ ▲ ○ ▲ – –
Odebiyi (2014) [31] n.r. n.r. – – ▲ ▲ – –
Ridner (2013) [32] n.r n.r. ○ ▲ ○ ▲
Bongi (2011) [27] None n.r. ▲ ▲ ▲ ▲ ▲ ▲
Holmes (2014) [30] 1 deep venous 
thrombosis
2 deep venous thrombosis, 1 
thrombophlebitis, 1 stocking 
allergy
– – – – – –
dos Santos Crisostomo (2015) [33] n.r. n.r. – – ○ – ○
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Comparison with other studies
Breast cancer patients are one of the largest groups of lym-
phoedema patients. CDT, MLD and bandaging have been 
shown to be effective in reducing lymphoedema volume 
[15], which was also described in the trials included in this 
review [28, 29]. A previous systematic review reported 
inconclusive results on the effect of MLD in the quality of 
life of patients with BCRL [18]. Our study includes four 
studies published since then [23, 28, 29, 31], most of which 
report no changes in HRQoL in comparison to the control 
groups. Lack of improvement in HRQoL after MLD inter-
ventions was also found in studies that were not eligible for 
this review because they included self-lymphatic drainage in 
the control group [33] or were non-randomised trials [34]. 
Breast cancer patients seem to have relatively high levels 
of HRQoL at baseline [23], which might affect the extent 
to which the overall HRQoL can be improved. One uncon-
trolled study, however, reported significant improvements 
in HRQoL after CDT compared to the control intervention 
[35].
Improvements were reported for certain HRQoL domains 
such as pain, heaviness, emotional function, dyspnoea and 
sleep disturbance [33] and should not be overlooked. Even 
though no study reported decreases in HRQoL after MLD 
interventions, lack of power to detect a negative association 
cannot be ruled out.
Non-pharmacological therapeutic options for oedema 
from chronic venous insufficiency include compression 
garments, movement and MLD [36]; the latter along the 
route of the venous vessels was shown to increase the blood 
flow in the deep and superficial veins [37]. Improvements 
in HRQoL were only described for patients who did not use 
stockings before the intervention. We excluded two studies 
of patients with chronic venous insufficiency because both 
patients with and without oedema were included; these were 
placebo-controlled trials that reported significant improve-
ments in HRQoL after MLD [12, 38]. While these results 
from placebo-controlled trials are promising, more trials 
with multimodal therapy programs are needed to quantify 
the relative contribution of MLD in CDT [18].
Systemic sclerosis is a rare but highly debilitating disease 
for which treatment options are scarce. The impact of any 
intervention on the HRQoL of the patients is of the utmost 
importance but MLD has been hardly ever studied [39]. The 
results reported here must be interpreted with caution, as 
they come from a single study.
The mechanisms through which MLD might lead to 
higher HRQoL are diverse but common to all patients. The 
pressure on the tissues reduces the microlymphatic hyper-
tension and stretches the lymph collector, increasing the 
lymphatic transport capacity, which results in decreased 
volume of the affected body part. Volume decrease may 
reduce discomfort (e.g. pain, tightness and heaviness) as 
well as improve the function of the affected body region 
[18]. Besides the effect on lymphatic vessels, the blood 
flow in superficial arteries and veins increases, improving 
wound healing and decreasing inflammatory makers [14]. 
Additionally, MLD is usually combined with skin care, exer-
cise, which have a positive effect on the HRQoL [40], and 
the role of social interaction and relaxation should not be 
disregarded [14].
Study limitations
The small number of eligible studies limits this review, as 
in some areas/aetiology of oedema only one or two studies 
were identified, and therefore conclusions must be drawn 
with caution. We searched six well-known databases, as 
well as the references of systematic reviews and of studies 
included, with the aim of identifying an exhaustive list of 
references. It is unlikely that important trials on the topic 
were missed.
Another important limitation comes from the small sam-
ple size of the eligible trials. This is particularly relevant 
because our results relied on the p values reported by the 
studies to take into account chance as an alternative expla-
nation for their results, and some trials may not have had 
statistical power to detect a significant effect of the MLD on 
HRQoL, should one exist.
Direct comparisons among the studies were also limited 
by the different HRQoL instruments used, which contained 
items for different domains. Disease- and condition-specific 
questionnaires do not always measure the same domains, and 
generic HRQoL scales might not capture the symptoms of 
lymphoedema sufficiently.
In most studies MLD was offered in combination with 
physical exercise, skin care, compressive garments or other 
innovative interventions. These interventions may have a 
positive impact in the HRQoL of the patients, and therefore 
the effect reported in the trials may not be directly compa-
rable to trials that offered MLD only.
Implications for practice and future research
In the absence of evidence showing that MLD has an adverse 
effect in HRQoL, doctors and therapists should emphasise 
the benefits in volume reduction and potential positive 
effects on some HRQoL domains to their patients (e.g. for 
vitality [31]).
More high-quality studies, in patients with oedema at dif-
ferent locations and of different severity, are needed to pro-
vide a definitive answer to this question. If MLD proves to 
have a positive effect on the HRQoL of patients with chronic 
oedema, more research is needed to find an optimal treat-
ment duration and frequency, and to quantify the relative 
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contribution of the treatment effect of MLD in multimodal 
therapy concepts [1, 17].
Conclusions
In conclusion, the effect of MLD on the HRQoL of the 
patients with chronic oedema is unclear. However, MLD is 
a well-tolerated, accepted and safe treatment technique with 
shown benefits for oedema volume reduction that should be 
continued in the absence of evidence for a negative impact 
on the HRQoL of the patients.
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